Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 701–800 of 1,014
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 42
“A well-known example from AD is monitoring for amyloid-related imaging abnormalities (ARIA) [5, 12, 90, 128, 129].”
BackgroundMethodInfluentialAmyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 45
Akamatsu, G., Ikari, Y., Ohnishi, A., Nishida, H., Aita, K., Sasaki, M., Yamamoto, Y., Sasaki, M., & Senda, M. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/15/5768 · Cited by 43
Chiasserini, D., Biscetti, L., Farotti, L., Eusebi, P., Salvadori, N., Lisetti, V., Baschieri, F., Chipi, E., Frattini, G., Stoops, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160298 · Cited by 42
“The availability of an unbiased test to categorize the enrolled patients may help to reduce the chance of including patients whose cognitive deficit is not underlined by AD pathology [5].”
Sun, X., Yu, X., Zhu, J., Li, L.-J., Zhang, L., Huang, Y., Liu, D., Ji, M., Sun, X., Zhang, L. L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01273-8 · Cited by 52
Li, Q. S., Parrado, A. R., Samtani, M. N., Narayan, V. A., & Initiative, A. D. N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134000 · Cited by 40
“For example, we know that up to 36.1% of APOE ε4 allele non-carriers clinically diagnosed with Alzheimer’s Dementia do not have Alzheimer’s pathology as measured by PIB-PET.”
BackgroundInfluentialThai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Ellis, K. A., Rainey-Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
“Furthermore, as clinical trials of drugs designed to reduce Aβ toxicity are typically conducted over intervals of 18-months [23,24], it is important to determine whether the ε4 exacerbation of Aβ related cognitive decline requires more than 18 months to become evident, or whether the absence of such effects in studies…”
BackgroundImmunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
St‐Amour, I., Cicchetti, F., & Calon, F. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1518-9 · Cited by 42
“The absence of benefits in a phase III clinical trial involving bapineuzumab also prompted abortion of the study [131].”
BackgroundBerlyand, Y., Weintraub, D. A., Xie, S. X., Mellis, I. A., Doshi, J. J., Rick, J. H., McBride, J. D., Davatzikos, C. A., Shaw, L. M. J., Hurtig, H. I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147319 · Cited by 41
Tau-imaging in neurodegeneration
Bischof, G. N., Endepols, H., van Eimeren, T., & Drzezga, A. E. (2017) · Methods · doi:10.1016/j.ymeth.2017.08.003 · Cited by 41
“However, unfortunately, numerous therapeutic efforts targeted against ß-amyloid accumulation have not yet met the expectations [2, 3].”
BackgroundRecent Advances: Decoding Alzheimer’s Disease With Stem Cells
Fang, Y., Gao, T., Zhang, B., & Pu, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00077 · Cited by 42
“Recently, several pioneering spotlighted trials targeting Aβ have met with dissatisfying results in terms of improved cognitive function (Doody et al., 2013; Salloway et al., 2014).”
BackgroundClinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
Brashear, H. R., Ketter, N., Bogert, J., Di, J., Salloway, S. P., & Sperling, R. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180675 · Cited by 39
Self-citationZeng, Q., Li, L., Yu, J., Chen, Z., Duan, L., Cao, M., Ma, M., & Wu, Z. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/8706589 · Cited by 51
ApoE mimetic improves pathology and memory in a model of Alzheimer’s disease
Krishnamurthy, K., Cantillana, V., Wang, H., Sullivan, P. M., Kolls, B. J., Ge, X., Lin, Y., Mace, B., & Laskowitz, D. T. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146685 · Cited by 39
Feng, Y., Li, X., Ji, D., Tian, J., Peng, Q., Shen, Y., & Xiao, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.123125 · Cited by 41
Multiple Targets for the Management of Alzheimer’s Disease
Ahmad, S., Akhtar, S., Jamal, Q. M. S., Rizvi, S. M. D., Kamal, M. A., Khan, M. K., & Siddiqui, M. H. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161003165855 · Cited by 41
Qiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 49
“3 Significance of epitope specificity in determining the efficacy of antibodies targeting Aβ was observed among individuals who carried the APOE ε4 allele, which aligns with findings from other trials involving antibodies that target plaques [16, 33, 47, 63, 64].”
BackgroundResultImmunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model
Dorostkar, M. M., Burgold, S., Filser, S., Barghorn, S., Schmidt, B., Anumala, U. R., Hillen, H., Klein, C., & Herms, J. (2014) · Brain · doi:10.1093/brain/awu280 · Cited by 38
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
Stella, F., Radanovic, M., Canineu, P. R., de Paula, V. D. J. R., & Forlenza, O. V. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615592116 · Cited by 46
Dai, H., Hu, W.-Y., Jiang, L.-H., Li, L., Gaung, X., & Xiao, Z. (2016) · Scientific Reports · doi:10.1038/srep27600 · Cited by 40
Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
Vāvere, A. L., & Scott, P. J. H. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.05.001 · Cited by 42
Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Wang, Y., Yan, T., Lu, H.-H., Yin, W., Lin, B., Fan, W.-B., Zhang, X., & Fernandez-Funez, P. (2017) · Neurodegenerative Diseases · doi:10.1159/000478741 · Cited by 35
Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease
Chakravarthy, M., Chen, S., Dodd, P. R., & Veedu, R. N. (2017) · Theranostics · doi:10.7150/thno.21529 · Cited by 45
“Bapineuzumab Aβ aggregation inhibitor Phase III End points not significantly different [55]”
BackgroundCopper mediated amyloid-β binding to Transthyretin
Ciccone, L., Fruchart‐Gaillard, C., Mourier, G., Savko, M., Nencetti, S., Orlandini, E., Servent, D., Stura, E. A., & Shepard, W. (2018) · Scientific Reports · doi:10.1038/s41598-018-31808-5 · Cited by 40
Alleviation of symptoms of Alzheimer's disease by diminishing Aβ neurotoxicity and neuroinflammation
Yang, T., Zhu, Z., Yin, E., Wang, Y., Zhang, C., Yuan, H., Zhang, H., Jin, S., Guo, Z., & Wang, X. (2019) · Chemical Science · doi:10.1039/c9sc03042e · Cited by 39
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Li, L., Zou, Z., Liu, J., Xu, Z., Fu, Y., Tian, Y., & Zhang, W. (2021) · Chemical Science · doi:10.1039/d1sc00153a · Cited by 38
Madrasi, K. J., Das, R., Abdul, H. M., Lin, L., Hyman, B. T., Lauffenburger, D. A., Albers, M. W., Rissman, R. A., Burke, J. M., Apgar, J. F., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12312 · Cited by 44
Akhter, H., Ballinger, C., Liu, N., van Groen, T., Postlethwait, E. M., & Liu, R.-M. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv124 · Cited by 37
Tip-enhanced Raman spectroscopy of amyloid β at neuronal spines
Tabatabaei, M., Caetano, F. A., Pashee, F., Ferguson, S. S. G., & Lagugné‐Labarthet, F. (2017) · The Analyst · doi:10.1039/c7an00744b · Cited by 39
Korábečný, J., Špilovská, K., Mezeiová, E., Benek, O., Jůza, R., Kaping, D., & Soukup, O. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180517094023 · Cited by 40
Systematic Multi-Domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol
Yaffe, K. S., Barnes, D. E., Rosenberg, D. E., Dublin, S., Kaup, A. R., Ludman, E. J., Vittinghoff, E., Peltz, C. B., Renz, A. D., Adams, K. J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180634 · Cited by 44
Implications of Microorganisms in Alzheimer’s Disease
Yadav, P., Lee, Y., Panday, H., Kant, S., Bajwa, N., Parashar, R., Jha, S. K., Jha, N. K., Nand, P., Lee, S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100314 · Cited by 40
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease
Spotorno, N., Strandberg, O. T., Stomrud, E., Janelidze, S., Blennow, K., Nilsson, M., van Westen, D., & Hansson, O. (2023) · Brain · doi:10.1093/brain/awad428 · Cited by 48
Self-citationA β-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
Montoliu-Gaya, L., & Villegas, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.11 · Cited by 37
Weekman, E. M., Sudduth, T. L., Caverly, C. N., Kopper, T. J., Phillips, O. W., Powell, D. K., & Wilcock, D. M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1762-16.2016 · Cited by 52
“…reduced A levels and improved cognitive outcomes (Schenk et al., 1999; Morgan et al., 2000; Wilcock et al., 2004a, b); however, in clinical trials, anti-A immunotherapy failed to reach primary cognitive outcomes in several different clinical trials (Salloway et al., 2014; Siemers et al., 2016).”
BackgroundInfluentialAmyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease
Kim, Y. H., Lee, S.-M., Cho, S., Kang, J., Minn, Y., Park, H., & Choi, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41429-1 · Cited by 40
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Li, L., Miao, M., Chen, J., Liu, Z., Li, W., Qiu, Y., Xu, S., & Wang, Q. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15234 · Cited by 38
“However, previous attempts at therapeutics that eliminate Aβ have proven unsuccessful in preventing neuronal loss and cognitive dysfunction in AD (Nalivaeva & Turner, 2019; Salloway et al., 2014).”
BackgroundBiomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 46
Yin, Z., Zhang, Z., Gao, D., Luo, G., Ma, T., Wang, Y., Lu, L., & Gao, X. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c18060 · Cited by 40
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
“The time course of this atrophy is discordant with the time course of amyloid removal, which is evident in the study with bapineuzumab, that barely removed any amyloid from the brain (Salloway et al, 2014).”
ResultCheng, L., Li, W., Chen, Y., Lin, Y., Wang, B., Guo, Q., & Miao, Y. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327864 · Cited by 36
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Martin, L. J., & Qing, C. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly040 · Cited by 37
Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
Novak, P., Cehlar, O., Skrabana, R., & Novak, M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179942 · Cited by 37
“…all aspects of the proposed amyloid cascade have been tested, e.g.: • Immunotherapy aimed at removing the amyloid-(cid:2) (A (cid:2) ) peptide: ◦ active vaccines, e.g., AN1792 [33] and CAD106 [34]; ◦ passive vaccines, e.g., bapineuzumab [35], solanezumab[36],gantenerumab[37],adu-canumab[38].”
Ansart, M., Epelbaum, S., Gagliardi, G., Colliot, O., Dormont, D., Dubois, B., Hampel, H., Durrleman, S., & study, F. T. A. D. N. I. A. T. I.-P. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280218823036 · Cited by 37
“Slowing down the formation of Amyloid plaques at the beginning of the process, when individuals are not yet cognitively impaired, should have effects on the long run, 8,9 whereas on symptomatic individuals cognitive damage has already occurred and might not be reversed.”
Foroutan, N., Hopkins, R. B., Tarride, J., Flórez, I. D., & Levine, M. (2019) · Clinical and investigative medicine · doi:10.25011/cim.v42i1.32393 · Cited by 38
Flotillin is a Novel Diagnostic Blood Marker of Alzheimer’s Disease
Abdullah, M., Kimura, N., Akatsu, H., Hashizume, Y., Taslima, F., Tachita, T., Iida, S., Zou, K., Matsubara, E., & Michikawa, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190908 · Cited by 36
Application of CRISPR genetic screens to investigate neurological diseases
So, R. W. L., Chung, S., Lau, H. H. C., Watts, J. J., Gaudette, E. V., Al‐Azzawi, Z. A. M., Bishay, J., Lin, L. T., Joung, J., Wang, X., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0343-3 · Cited by 40
Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques
Ezzati, A., Harvey, D. J., Habeck, C. G., Golzar, A., Qureshi, I., Zammit, A. R., Hyun, J., Truelove‐Hill, M., Hall, C. B., Davatzikos, C. A., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191038 · Cited by 38
“In the last decade, many clinical trials have tried to use targeted therapies to lower brain A (cid:2) , but all these trials have failed to achieve significant effects on clinical endpoints [2–4].”
Endosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology
Arbo, B. D., Cechinel, L. R., Palazzo, R. P., & Siqueira, I. R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101006 · Cited by 38
N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 37
“We analysed the biosimilar Bapineuzumab and Crenezumab antibodies, which both had been evaluated in clinical trials and did not meet their primary endpoints [8,49,50].”
BackgroundInteractive rather than independent effect of APOE and sex potentiates tau deposition in women
Wang, Y.-T. T., Pascoal, T. A., Therriault, J., Kang, M. S., Benedet, A. L., Savard, M., Tissot, C., Lussier, F. Z., Arias, J. F., Mathotaarachchi, S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab126 · Cited by 37
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Puente, O. A., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., KIPROV, D. D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12477 · Cited by 40
AbdAlla, S., Hakim, A., Abdel-Baset, A., el Faramawy, Y., & Quitterer, U. (2015) · BioMed Research International · doi:10.1155/2015/917156 · Cited by 42
“In view of the recent failure of large clinical trials, which targeted β-amyloid plaques [13, 14], such alternative models, which imitate the disease process before the accumulation ofAβplaques, could become of substantial value.”
BackgroundPerche, F., Uchida, S., Akiba, H., Lin, C.-Y., Ikegami, M., Dirisala, A., Nakashima, T., Itaka, K., Tsumoto, K., & Kataoka, K. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666161108110031 · Cited by 36
“(7, 8) Further support for insufficient anti body delivery to the brain came for Bapineuzumab and Solaneumab Phase III clinical trials failures with decreased brain Aβ and hyper phosphorylated Tau levels without cognitive improvement.(9-11) In addition, Bapinezum ab caused dose-limiting vasogenic edema.”
BackgroundTau-negative amnestic dementia masquerading as Alzheimer disease dementia
Botha, H., Mantyh, W. G., Graff-Radford, J., Machulda, M. M., Przybelski, S. A., Wiste, H. J., Senjem, M. L., Parisi, J. E., Petersen, R. C., Murray, M. E., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005124 · Cited by 39
“Our findings plus prior reports have made it highly likely that many participants enrolled in AD dementia trials over the last few decades may not have had AD pathophysiology driving their clinical syndrome.(4,5,9) In addition, the presence of hippocampal atrophy in all participants and volume loss in other characteri…”
ResultTargeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
Menéndez‐González, M., Padilla-Zambrano, H., Alvarez, G., Capetillo‐Zarate, E., Tomás‐Zapico, C., & Costa, A. D. D. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00100 · Cited by 39
“Similarly, Bapineuzumab modifies Aβ accumulation and CSF biomarkers, but none of the trials showed a significant clinical benefit (Salloway et al., 2014).”
BackgroundKehoe, P. G., Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170101 · Cited by 35
“similar to those previously reported for multi-centre trials(60).”
Self-citationNonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 42
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 38
“This contrasts with datafromsolanezumabandbapineuzumabtreatments,whichareasso-ciated with no-to-mild decrease in amyloid-PET levels 33,34 and were not associated with clear changes in the density of A β deposits at autopsy,showingonlysubtlebiochemicalalterations.”
Alzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria
Höglund, K., Fourier, A., Perret‐Liaudet, A., Zetterberg, H., Blennow, K., & Portelius, E. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.041 · Cited by 46
Self-citationHoos, M. D., Vitek, M. P., Ridnour, L. A., Wilson, J., Jansen, M., Everhart, A., Wink, D. A., & Colton, C. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-50 · Cited by 35
Rabinovici, G. D., Karlawish, J., Knopman, D., Snyder, H. M., Sperling, R., & Carrillo, M. C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.002 · Cited by 36
“In various studies, as many as 15 percent to 25 percent of individuals who are diagnosed with AD dementia based on clinical symptoms (not brain PET imaging) do not have evidence of elevated beta-amyloid levels on PET imaging [8,9,18].”
BackgroundSelf-citationAmyloid formation: functional friend or fearful foe?
Bergman, P., Roan, N. R., Römling, U., Bevins, C. L., & Münch, J. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12479 · Cited by 43
Guo, T., Dukart, J., Brendel, M., Rominger, A., Grimmer, T., Yakushev, I. Y., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.013 · Cited by 39
“Thus, a standardized uptake value ratio (SUVR) in a composite cortical area averaged across these regions (referred to as AD-typical regions thereafter) has been commonly used as an end point in anti-amyloid trials [1,6,20].”
MethodWestwood, S., Baird, A. L., Hye, A., Ashton, N. J., Nevado-Holgado, A. J., Anand, S. N., Liu, B., Newby, D., Bazenet, C., Kiddle, S. J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00409 · Cited by 36
Diagnosis and treatment of cognitive impairment
Arnim, C. A. F. V., Bartsch, T., Jacobs, A. H., Holbrook, J. A., Bergmann, P., Zieschang, T., Polidori, M. C., & Dodel, R. C. (2019) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-019-01560-0 · Cited by 36
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 41
“Interesting findings involved the correlation between Aβ decrease and p-Tau decrease in the CSF because it was found only in APOE ε4 carrier patients and not in the non-carriers [102].”
BackgroundAmyloid beta peptide immunotherapy in Alzheimer disease
Delrieu, J., Ousset, P., Voisin, T., & Vellas, B. J. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.10.003 · Cited by 39
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
Waring, J. F., Tang, Q., Robieson, W., King, D. P., Das, U., Dubow, J. S., Dutta, S., Marek, G. J., & Gault, L. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142589 · Cited by 37
Walsh, C., Drinkenburg, W. H. I. M., & Ahnaou, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.020 · Cited by 39
Pankiewicz, J. E., Baquero-Buitrago, J., Sanchez, S., Lopez-Contreras, J., Kim, J., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0156-1 · Cited by 41
“However one needs to be mindful that escalation of antiAβ mAbs dose in APOE ε4 allele carriers may trigger increased rate of vasculotropic adverse events associated with immunization [5, 8, 14].”
BackgroundThe role of positron emission tomography imaging in understanding Alzheimer’s disease
Barthel, H., Seibyl, J. P., & Sabri, O. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1023296 · Cited by 38
“Recently, there has been intense interest in AD therapeutics designed to ameliorate or reduce brain amyloid burden [21].”
BackgroundAndreasen, N., Simeoni, M., Ostlund, H., Lisjo, P. I., Fladby, T., Loercher, A. E., Byrne, G. J., Murray, F., Scott-Stevens, P. T., Wallin, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0098153 · Cited by 34
“Our findings are in contrast with those obtained with anti-AβmAbs bapineuzumab and gantenerumab, which are known to cause ARIA-E [2, 6, 9].”
InfluentialImproving drug delivery technology for treating neurodegenerative diseases
Choonara, Y. E., Kumar, P., Modi, G., & Pillay, V. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1162152 · Cited by 35
Rauth, S., Hinz, D., Borger, M. A., Uhrig, M., Mayhaus, M., Riemenschneider, M. J., & Skerra, A. (2016) · Biochemical Journal · doi:10.1042/bcj20160114 · Cited by 39
Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi, K., Kidana, K., Tatebe, T., & Tomita, T. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26129 · Cited by 40
“However, a phase 3 trial of bapineuzumab showed no clinical benefits compared with placebo [Salloway et al., 2014].”
BackgroundCurrent status and future challenges for molecular imaging
Anderson, C. J., & Lewis, J. S. (2017) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2017.0023 · Cited by 36
Chang, K. L., Wong, L. R., Pee, H. N., Yang, S., & Ho, P. C. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1586-2 · Cited by 35
Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review
Fouad, G. I. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0078-x · Cited by 34
“Another type of treatment, such as anti-Aβ aggregation agents and β-secretase inhibitors, is aimed to prevent amyloid plaque formation and to facilitate amyloid clearance (Huang and Mucke 2012; Salloway et al. 2014).”
BackgroundRationale for the development of an Alzheimer’s disease vaccine
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 33
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 38
“phase III, however, no success was achieved [61].”
BackgroundDementia treatment versus prevention
Perneczky, R. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/rperneczky · Cited by 45
New insights in drug development for Alzheimer's disease based on microglia function
Qiao, O., Ji, H., Zhang, Y., Zhang, X., Zhang, X., Liu, N., Huang, L., Liu, C., & Gao, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111703 · Cited by 35
Incident stroke in patients with Alzheimer’s disease: systematic review and meta-analysis
Pinho, J., Quintas-Neves, M., Dogan, I., Reetz, K., Reich, A., & Costa, A. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-95821-x · Cited by 37
Chen, L., Cruz, E., Oikari, L. E., Padmanabhan, P., Song, J. H., & Götz, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114517 · Cited by 38
New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
M. Wilkins, H., & K. Morris, J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 35
Schwarz, C. G., Jones, D. T., Gunter, J. L., Lowe, V. J., Vemuri, P., Senjem, M. L., Petersen, R. C., Knopman, D. S., Jack, C. R., & Initiative, T. A. D. N. (2017) · Human Brain Mapping · doi:10.1002/hbm.23622 · Cited by 37
“…of b -amyloid from Positron Emission Tomography (PET) scans for clinical trials and longitudinal observational studies of Alzheimer’s disease (AD) are typically calculated using the Standardized Uptake Value Ratio (SUVR) [Jagust et al., 2010; Salloway et al., 2014; Siemers et al., 2016].”
MethodCerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments
Lista, S., Zetterberg, H., Dubois, B., Blennow, K., & Hampel, H. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7366-z · Cited by 40
Self-citationWang, T., Xie, X.-X., Ji, M., Wang, S., Zha, J., Zhou, W.-W., Yu, X., Chen, W., Ma, S., Xi, Z.-Y., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.015 · Cited by 36
DeBay, D. R., Reid, G. A., Macdonald, I. R., Mawko, G., Burrell, S., Martin, E. V., Bowen, C. V., & Darvesh, S. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.009 · Cited by 37
Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice
Kopec, B. M., Zhao, L., Rosa‐Molinar, E., & Siahaan, T. J. (2020) · Medical Research Archives · doi:10.18103/mra.v8i2.2043 · Cited by 36
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Neural circuit changes in neurological disorders: Evidence from in vivo two-photon imaging
Xiong, H., Tang, F., Guo, Y., Xu, R., & Peng, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101933 · Cited by 36
Keramidis, I., McAllister, B. B., Bourbonnais, J., Wang, F., Isabel, D., Rezaei, E., Sansonetti, R., Degagne, P., Hamel, J. P., Nazari, M., et al. (2023) · Brain · doi:10.1093/brain/awad250 · Cited by 40
“39 40–42 These findings suggest that A β initiates a pathological process that, once sufficiently advanced, can no longer be reversed by targeting A β itself.”
Background
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.